Paediatric‐onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis

Neuronal ceroid lipofuscinoses (NCLs) are rare, progressive disorders. Through this series of 20 patients with NCL, we illustrate differences between subtypes in their presenting symptoms and clinical, imaging, and electrophysiological results to raise awareness of symptom diversity. Data were available on presenting symptoms, genetics, magnetic resonance imaging (MRI), electroencephalography (including with low‐frequency intermittent photic stimulation), visual responses, and electron microscopy. Causal mutations were identified in 10 patients. Eleven patients had neuronal ceroid lipofuscinosis type 2 (CLN2) disease and their most common presenting symptom was seizures, although motor and language defects were also reported. Five patients with CLN2 disease showed abnormalities at initial MRI, but only three showed a photic response with low‐frequency stimulation. Seizures were not as common a presenting symptom in other NCL subtypes. Patients with NCLs present with diverse symptoms, which may not be characteristic in early disease stages. These signs and symptoms should lead to rapid diagnostic confirmatory testing for NCLs.

[1]  S. Berkovic,et al.  Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis , 2019, The Lancet Neurology.

[2]  B. Kosofsky,et al.  Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. , 2018, The Lancet. Child & adolescent health.

[3]  D. Rakheja,et al.  Neuronal ceroid-lipofuscinoses , 2018, Translational Science of Rare Diseases.

[4]  M. V. van Genderen,et al.  Timing of cognitive decline in CLN3 disease , 2018, Journal of Inherited Metabolic Disease.

[5]  F. Vigevano,et al.  Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease , 2017, Epilepsia.

[6]  A. Berezovsky,et al.  Retinal function in patients with the neuronal ceroid lipofuscinosis phenotype. , 2017, Arquivos brasileiros de oftalmologia.

[7]  J. Mink,et al.  Management Strategies for CLN2 Disease. , 2017, Pediatric neurology.

[8]  E. Baker,et al.  MRI Brain Volume Measurements in Infantile Neuronal Ceroid Lipofuscinosis , 2017, American Journal of Neuroradiology.

[9]  S. Berkovic,et al.  Recurrent generalized seizures, visual loss, and palinopsia as phenotypic features of neuronal ceroid lipofuscinosis due to progranulin gene mutation , 2014, Epilepsia.

[10]  J. Mink,et al.  NCL diseases - clinical perspectives. , 2013, Biochimica et biophysica acta.

[11]  S. Mole,et al.  New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses , 2012, Neurology.

[12]  M. Haltia The neuronal ceroid-lipofuscinoses: from past to present. , 2006, Biochimica et biophysica acta.

[13]  R. Boustany,et al.  Clinicopathological and molecular characterization of neuronal ceroid lipofuscinosis in the Portuguese population , 2003, Journal of Neurology.